Similarly, a small molecule screen identified MSU38225 as an inhibitor of NRF2 which enhances NRF2 proteasomal degradation and sensitizes NRF2-active tumor cells to chemotherapy [92]. The gene discussed is NFE2L2; the disease is neoplasm.